Principal at PCMS1 Consulting, advises large caps, start-ups, and NGOs on issues surrounding the access and distribution of life-saving medicines in emerging markets and low- and middle-income countries. He offers 30+ years of commercial leadership experience in the biopharmaceutical industry, with more than two decades at Gilead Sciences in leadership roles across sales, managed markets, and global commercial operations. Clifford consults on biopharma investment opportunities, early-stage clinical studies, and go-to-market strategies in emerging markets and low/middle-income countries. Having built multiple global strategic partnerships, including collaborations with governments, non-governmental organizations, and generic drug manufacturers, he is able to facilitate the delivery of critical medicines internationally in very complex/opaque markets. His expertise extends to matters such as the implications of holding market authorization rights and the role of voluntary licensing in ensuring that life-saving medical innovations are available to resource-challenged areas globally. From 2007 to 2020, Clifford served at Gilead Sciences, culminating with SVP, Global Patient Solutions, with responsibility for more than 140 countries. His successful initiatives in emerging markets drove both access to medicines and ROI in geographies spanning Latin America and the Caribbean, Africa, South/Southeast Asia Pacific, and Eastern Europe. Leveraging a deep knowledge of the regulatory landscape and distribution network across the globe, Clifford spearheaded Gilead’s entry into generic licensing agreements with companies in Pakistan, India, and South Africa that created a competitive market for generic HIV and hepatitis B & C medicines, and most recently, Remdesivir to treat COVID-19. His efforts resulted in the provision of medicines to more than 19 million people living with HIV/AIDS in these resource-limited countries. In 2022, Clifford was granted a fellowship at the Berkman Klein Center for Internet & Society at Harvard University to explore voluntary licensing and access to medicines in the context of pandemics and health emergencies. He is a Fellow of the American Institute for Medical and Biological Engineering (AIMBE). He sits on the Board of Antiva Biosciences and the MTV Staying Alive Foundation, and serves as a business advisor to Siolta Therapeutics, Pardes Biosciences, and Karkinos Healthcare (India). A graduate of the New Jersey Institute of Technology (NJIT) with a BS in Mechanical Engineering, he received an Honorary PhD from his alma mater and sits as a member of the Industrial Advisory Board for NJIT’s Albert Dorman Honors College. He is also the recipient of an Edward F. Weston Medal for Professional Achievement and was inducted as a member of the National Academy of Engineering in 2019.